| 项目编号 | PRJCA024983 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 项目标题 | CHOICE01-ctDNA | ||||||||
| 涉及领域 | Medical | ||||||||
| 数据类型 | Variation | ||||||||
| 物种名称 | Homo sapiens | ||||||||
| 描述信息 | CHOICE-01 was a multicentered, randomized, placebo-controlled, double-blinded phase III trial conducted in 59 medical centers across China, assessing the efficacy and safety of chemotherapy plus toripalimab, an anti-PD-1 antibody, in treatment-naive patients with locally advanced (Stage IIIB or IIIC) or metastatic NSCLC without EGFR or ALK driver mutations. | ||||||||
| 样品范围 | Multiisolate | ||||||||
| 发布日期 | 2024-04-06 | ||||||||
| 项目资金来源 |
|
||||||||
| 提交者 | Jie Wang (zlhuxi@163.com) | ||||||||
| 提交单位 | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences | ||||||||
| 提交日期 | 2024-04-06 |
| 资源名称 | 描述 |
|---|---|
| BioSample (654) show | - |